Europe will have to wait for Ascendis Pharma's weekly growth hormone

The Danish biotech firm will not be launching its weekly drug until mid-2023 in Europe, despite already having marketing authorization in the region, Ascendis reveals in its second-quarter report.
Photo: Kevin Grønnemann
Photo: Kevin Grønnemann
by mikkel aabenhus hemmingsen, translated by daniel pedersen

Ascendis Pharma, which is based in Copenhagen, Denmark, is busy getting growth hormone Skytrofa established on the US market, which means Europe will have to take a back seat.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading